Literature DB >> 19071095

CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.

Moeko Noguchi-Shinohara1, Takahiko Tokuda, Mitsuhiro Yoshita, Takashi Kasai, Kenjiro Ono, Masanori Nakagawa, Omar M A El-Agnaf, Masahito Yamada.   

Abstract

Dementia with Lewy bodies (DLB) is characterized by widespread depositions of alpha-synuclein, which are described as Lewy bodies. Recently, it was shown that neuronal cells in culture constitutively release alpha-synuclein into the culture medium and that alpha-synuclein is normally present in human cerebrospinal fluid (CSF). The aim of the present study was to evaluate the diagnostic value of CSF alpha-synuclein levels in discriminating DLB from Alzheimer's disease (AD). Alpha-synuclein was measured in CSF from 16 patients with DLB and 21 patients with AD. Iodine-123 metaiodobenzylguanidine cardiac scintigraphy was also performed to assess Lewy body pathology. CSF alpha-synuclein levels did not differ significantly between DLB and AD patients. However, the duration of illness was associated with lower alpha-synuclein levels (p<0.05) in DLB, while no such association was found in AD. The present data show CSF alpha-synuclein levels are not sensitive diagnostic markers to discriminate DLB from AD. However, the lower alpha-synuclein levels in DLB patients with longer duration suggest a reduction in CSF alpha-synuclein in association with increased severity of alpha-synucleinopathy in the brain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19071095     DOI: 10.1016/j.brainres.2008.11.055

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  30 in total

1.  CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.

Authors:  Michael R Sierks; Gaurav Chatterjee; Claire McGraw; Srinath Kasturirangan; Philip Schulz; Shalini Prasad
Journal:  Integr Biol (Camb)       Date:  2011-11-10       Impact factor: 2.192

Review 2.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

Review 3.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

4.  Brain Atrophy of Secondary REM-Sleep Behavior Disorder in Neurodegenerative Disease.

Authors:  Hee-Jin Kim; Hyung Kyun Im; Juhan Kim; Jee-Young Han; Mony de Leon; Anup Deshpande; Won-Jin Moon
Journal:  J Alzheimers Dis       Date:  2016-04-05       Impact factor: 4.472

Review 5.  Cerebrospinal fluid biomarkers in Parkinson disease.

Authors:  Lucilla Parnetti; Anna Castrioto; Davide Chiasserini; Emanuele Persichetti; Nicola Tambasco; Omar El-Agnaf; Paolo Calabresi
Journal:  Nat Rev Neurol       Date:  2013-02-19       Impact factor: 42.937

6.  Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature.

Authors:  Wei Tang; Qiong Huang; Yu-You Yao; Yan Wang; Yi-Le Wu; Zheng-Yu Wang
Journal:  J Neural Transm (Vienna)       Date:  2014-05-10       Impact factor: 3.575

Review 7.  Emerging biomarkers in cognition.

Authors:  Meredith Wicklund; Ronald C Petersen
Journal:  Clin Geriatr Med       Date:  2013-11       Impact factor: 3.076

8.  Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening.

Authors:  Michael Bidinosti; Derya R Shimshek; Brit Mollenhauer; David Marcellin; Tatjana Schweizer; Gregor P Lotz; Michael G Schlossmacher; Andreas Weiss
Journal:  J Biol Chem       Date:  2012-07-27       Impact factor: 5.157

9.  Cerebrospinal fluid biomarkers for dementia with lewy bodies.

Authors:  Elizabeta B Mukaetova-Ladinska; Rachael Monteith; Elaine K Perry
Journal:  Int J Alzheimers Dis       Date:  2010-10-17

Review 10.  Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies.

Authors:  Adrien W Schmid; Bruno Fauvet; Marc Moniatte; Hilal A Lashuel
Journal:  Mol Cell Proteomics       Date:  2013-08-21       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.